Landon Trost Peyronie’s Disease: CCH vs Surgery
New Data Suggests Non-Surgical Treatment May Be Preferred for Peyronie’s Disease
Table of Contents
Understanding the findings
Recent research presented at the 26th Annual Fall Scientific Meeting of the Sexual medicine Society of North America (October 9-12, 2025, Grapevine, Texas) indicates that a non-surgical approach to Peyronie’s disease may offer significant advantages over penile surgery.The study, detailed in Abstract 096, followed 40 men randomly assigned to either a collagenase clostridium histolyticum (CCH) treatment regimen combined with traction therapy (RestoreX) and sildenafil, or penile surgery also combined with traction and sildenafil.
Surgery Linked to Higher Rates of Complications
Three-year follow-up data revealed a notably higher incidence of complications among patients who underwent surgery. 92% of men in the surgery group reported experiencing some degree of penile length loss, compared to only 46% in the CCH group (P < .001). Furthermore,current pain was reported by 42% of surgery patients versus 8% of those receiving CCH (P = .04), and decreased or abnormal sensation was observed in 45% versus 27% respectively (P = .03).
While other adverse events were comparable between the two groups, these findings suggest a potential trade-off between surgical intervention and quality of life. The study highlights the importance of considering the potential for length loss, pain, and altered sensation when discussing treatment options with patients.
Patient Preference and a shift in Treatment Paradigm
Interestingly, patient willingness to repeat the therapy was similar in both groups, ranging from 75% to 77%. this suggests that despite the potential for complications, patients generally found both treatment approaches acceptable. The data presented is prompting a re-evaluation of long-held beliefs about Peyronie’s disease treatment.
The research suggests that CCH treatment may become the preferred first-line option, reserving surgery as a backup when CCH is not viable.This represents a significant shift, as surgery has traditionally been considered the standard treatment for Peyronie’s disease for over 60 years.